

*Note:* Page numbers in *italics* indicate figures.  
Page numbers followed by a “t” indicate tables.  
Clinical trials and studies are indexed under the acronym of the name;  
cross-references are provided from the full name.

- 4 D's mnemonic (diet, drugs, disorders of metabolism, diseases), 79  
4S (Scandinavian Simvastatin Survival Study), 132, 160-161, 166t, 268  
10-year risk assessments, 102, 104t-107t, 378
- A-Z trial (Phase Z), 133t, 137-138, 168t  
ABC A1, 28, 45, 288, 294, 353, 360  
ABC C2, 285  
ABCAG1 protein, 29  
ABCAG5 protein, 36t, 41  
ABCAG8 protein, 36t, 41  
Abdominal aortic aneurysm, 378  
Abetalipoproteinemia, 25  
ACAPS (Asymptomatic Carotid Artery Progression Study), 147, 148t, 149, 194t  
ACC. See *American College of Cardiology*.  
ACCORD (Action to Control Cardiovascular Risk in Diabetes) trial, 189-193, 299, 361  
ACE (angiotensin-converting enzyme) inhibitors, 136, 380  
Acquired causes of dyslipidemia. See *Secondary hyperlipoproteinemias*.  
ACT (assemble-calculate-treat to goals), 377-381  
    assemble component, 377-378  
    calculate component, 378-380, 379t  
    treat to goals component, 380-381  
Action to Control Cardiovascular Risk in Diabetes trial. See *ACCORD trial*.  
Acute coronary syndromes, 123-141. See also *Atherosclerosis and acute coronary syndromes*.  
    AHA criteria/grading system, 125t  
    chronic processes, 124-127, 126, 127t  
    clinical features, 127-132  
    clinical tips for, 126  
    lipid-lowering impacts on, 132-138  
    risk factors, 126-127, 127t, 129-131  
ADA. See *American Diabetes Association*.  
ADMIT (Arterial Disease Multiple Intervention Trial), 291-292  
Adolescents. See also *Children*.  
    CHD/CVD risk, 325-329  
    classification of cholesterol levels in, 326t  
    clinical tips, 325-326, 327, 328, 330, 331  
    diet and TLC for, 326-327  
    drug therapy for, 328, 329-331  
    goals of therapy, 326t  
    NCEP recommendations for, 325, 326t  
Adult Treatment Panel. See *ATP I, II, and III*.  
ADVANCE trial, 361  
Adverse effects and interactions  
    bile acid sequestrants, 282-283  
    cholesterol absorption inhibitor, 286-287  
    fibric acid derivatives, 299-301, 299t  
    fish oils, 303  
    HMG-CoA reductase inhibitors (statins), 268-273, 269t  
    nicotinic acid (niacin), 290-293, 290t

Advicor, 259t, 279t, 308  
 AFCAPS/TexCAPS (Air Force/Texas Coronary Atherosclerosis Prevention Study), 15, 100, 132, 175, 176t, 335  
 Age, CHD risk and, 102t, 104t-107t, 378. See also *Elderly patients*.  
 Aggressive vs Conventional Lipid Lowering on Atherosclerosis Progression trial (ASAP), 194t  
 AHA. See *American Heart Association*.  
 Air Force/Texas Coronary Atherosclerosis Prevention Study.  
     See *AFCAPS/TexCAPS*.  
 Alanine aminotransferase (ALT), 137, 151  
 Alcohol consumption, 80t, 114, 224-225  
 Algorithm, treatment. See *Treatment algorithm*.  
 ALLHAT-LLA (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial-Lipid-Lowering Arm), 176t, 181  
 ALOHA strategies, 338-340, 339t  
 Alpha linolenic acid (ALA), 225-226  
 Altocor, 259t. See also *Lovastatin*.  
 American Academy of Pediatrics, 328-329  
 American College of Cardiology (ACC), 120t  
 American Diabetes Association (ADA), 120t, 361  
 American Heart Association (AHA)  
     atherosclerosis criteria/grading system, 125t  
     on drug therapy for children/adolescents, 328  
     guidelines for lipid treatment in diabetics, 361  
     Prevention Conference V (on apo B in treatment algorithms), 100  
 Amiodarone, 84  
     drug interactions, 274, 274t  
 Anabolic steroids, 71, 84  
 Androgenic anabolic steroids, 71, 84  
 Androgens, lipid levels and, 84  
 Angina pectoris, 62, 127  
 Angiographic trials, 143-146, 144, 157-160. See also *Clinical trials and research studies*.  
     double-drug trials, 157-160, 162t-163t  
     monotherapy trials, 143-146  
     multiple intervention trials, 157-160, 164t  
     resin trials, 145t  
 Angiography  
     intravascular ultrasound vs, 63, 64  
     lipids in patients with premature CAD, 60t  
 Angiotensin-converting enzyme inhibitors (ACE inhibitors), 136, 380  
 Angiotensin receptor blockers (ARBs), 136, 380  
 Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA). See *ASCOT-LLA*.  
 Ankle-brachial index, 107, 110t, 129, 336  
 Anorexia, 80t, 81  
 Antara. See also *Fenofibrates*.  
     cost, 278t, 301  
     preparations and dosing regimen, 258t, 294t  
 Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial-Lipid-Lowering Arm trial. See *ALLHAT-LLA*.  
 Antihypertensives, 82-84, 82, 380  
 Antioxidants, 230-231, 339  
 Antipsychotic drugs, 88  
 Antiretroviral therapies, 87-88  
 Apheresis trials, 182-183, 184t, 266  
 Apolipoproteins, 23-25, 57  
     apo(a), 32  
     apo A-I, 28, 294  
     apo A-I Milano, 118  
     apo A-II, 294  
     apo A-V, 26, 43t, 44  
     apo B  
         clinical appraisal of, 119, 120t  
         fibrates and, 295  
         goals for, 119, 120t  
         insulin resistance and, 353, 355  
         measurement of, 56, 57  
         nicotinic acid and, 288  
         screening for, 100-101  
     apo B-48, 25  
     apo B-100, 26, 27, 32  
         in atherosclerosis, 100, 129  
         in familial combined hyperlipidemia, 36-38, 36t  
         familial defective, 36t, 39, 55t, 65  
         in hypertriglyceridemias, 43t  
     apo C-I, C-II, C-III, 25, 157, 294  
         in hypertriglyceridemias, 43t, 44, 45  
     apo E, 25, 26  
         E-II and E-IV phenotypes, 214  
         in severe primary polygenic LDL elevation, 36t, 40  
         in type III hyperlipoproteinemia (familial dysbetalipoproteinemia), 41-42, 41t  
 ARBITER and ARBITER-2 (Arterial Biology for Investigation of the Treatment of Reducing Cholesterol) trial, 194t  
 Arterial Disease Multiple Intervention Trial. See *ADMIT*.  
 ASAP (Aggressive vs Conventional Lipid Lowering on Atherosclerosis Progression) trial, 194t  
 ASCOT-LLA (Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm), 175-179, 176t, 181-182, 193, 342  
 Asian patients, 179-180  
 Aspartate transaminase, 151  
 Aspirin  
     with nicotinic acid, 292-293  
     routine use, 340, 381  
 Assemble component (ACT; treatment algorithm), 377-378  
 ASTEROID trial, 155-156  
 Asymptomatic Carotid Artery Progression Study. See *ACAPS*.  
 Atazanavir, 87  
 Atenolol, 83  
 Atheroma, 144, 149-151, 152t  
 Atherosclerosis and acute coronary syndromes, 123-141  
     acute coronary syndrome, clinical features, 127-132  
     AHA criteria/grading system, 125t  
     apo B levels and, 100, 129  
     chronic processes of, beginning in youth, 124-127, 126  
     clinical features, 127-132, 130t  
     clinical tips for, 126  
     clinical trials relating to, 132-138, 133t  
     familial combined hyperlipidemia and, 38  
     lipid-lowering impacts on, 132-138  
     lipoproteins and, 30-34, 31t-33t  
     plaque (stable and unstable), 129-132, 130t  
     premature atherosclerosis, 40-41

Atherosclerosis and acute coronary syndromes (*continued*)

- prevalence with age, 126
  - progression and development of, 123
  - risk factors, 126-127, 127t, 129-131
  - subclinical atherosclerosis, testing for, 107, 110t
- Atkins diet, 222-224, 223
- Atorvastatin, 93, 255
- in children/adolescents, 329
  - clinical trials, 132-133, 133t, 135t, 136-137, 151-155, 154t
  - primary prevention, 175-179, 176t-177t, 181-182, 190t, 193
  - RADIANCE-1, 197, 198t
  - secondary prevention, 168t-169t, 173-174
  - torcetrapib with, 197-199
  - vs pravastatin, 151-155, 154t, 166t, 173
- cost, 278t
- drug interactions, 274, 275t
  - efficacy, 263, 264t
  - high-dose, 136, 196
  - mechanism of action, 256
  - metabolic parameters, 260-262, 261t
  - preparations and dosing regimens, 136, 196, 259t
- ATP cassette transporter A1. See *ABCA 1*.
- ATP I (Adult Treatment Panel I), guidelines, 14-15, 14t
- ATP II (Adult Treatment Panel II), 15, 20-21, 20t, 21t
- ATP III (Adult Treatment Panel III), 15-18
- classification, 57
  - clinical appraisal and therapy goals, 99-122. See also *Clinical appraisal and therapy goals*.
  - on combination therapy, 307
  - dietary recommendations, 211-212, 212t
  - on elderly patients, 340
  - exercise and metabolic syndrome, 241
  - guidelines, 15-18, 16t, 19
  - ACT (assemble-calculate-treat to goals), 377-381
  - lipid treatment in diabetics, 361
  - update to, 15, 103, 340, 378-380
  - lipid/cholesterol level goals, 16t
  - lipid screening, 99-101
- Atromid-S. See *Clofibrate*.
- Autosomal recessive hypercholesterolemia, 36t, 40
- Azole antifungals, 274, 274t
- B<sub>6</sub> and B<sub>12</sub> (vitamins), 232-233, 234t-235t, 339
- BECAIT (Bezafibrate Coronary Atherosclerosis Intervention Trial), 183-185, 186t, 296
- β-adrenergic blocking agents, 136
- as secondary cause of dyslipidemia, 80t, 81
  - uses of, 81, 83
- β-blocker eye drops, 88
- β-Blocker Heart Attack Trial (BHAT), 83
- Beta sitosterolemia, 36t, 40-41
- β-stimulating drugs, 88-89
- Bezafibrate, 118, 293
- clinical trials (BECAIT, BIP), 118, 183-188, 186t, 296-297
  - dosing, 294t
- Bezafibrate Coronary Atherosclerosis Intervention Trial. See *BECAIT*.
- Bezafibrate Infarction Program. See *BIP*.

- BHAT (β-Blocker Heart Attack Trial), 83
- Bile acid sequestrants, 276-284
- adverse effects, 282-283
  - clinical tips, 277
  - clinical trials, 145t, 382
  - in combination therapies, 304t, 306, 307
  - bile acid sequestrants/ezetimibe, 304t, 305
  - bile acid sequestrants/fibric acid derivatives or n-3 fatty acids, 307
  - bile acid sequestrants/nicotinic acid, 304t, 306, 307
  - bile acid sequestrants/statins, 304t, 305
  - bile acid sequestrants/statins/nicotinic acid, 304t, 306
  - doses and side effects in, 306
  - contraindications, 117
  - cost, 278t, 284
  - for diabetic patients, 363
  - drug interactions, 274t, 283-284
  - efficacy for lipids and glycemic control, 281-282, 281t
  - hints to improve compliance, 283
  - indications for, 256t
  - mechanism of action and drug metabolism, 256t, 277-279
  - side effects, 277
  - statins and, 274, 275t
- Biliary obstruction, 80t
- BIP (Bezafibrate Infarction Program), 185-188, 186t, 296
- Blood pressure, high. See *Hypertension*.
- BMI. See *Body mass index*.
- Body fat distribution, 347
- Body mass index (BMI), 344-345, 345t, 347-351, 348, 350
- Bogalusa Heart Study, 331
- Bone marrow transplantation, 87
- Bone, statin benefits for, 268
- BUN/creatinine, 342
- C-reactive protein (CRP), 137-138, 155, 294
- ultrasensitive, 112, 129, 336
- CABG (coronary artery bypass graft) surgery, 171t, 172-173
- CAD (coronary artery disease)
- familial hypercholesterolemia/hyperlipidemia and, 62-64
  - Lp(a) as predictor of severity of, 72
  - post-CABG (coronary artery bypass) trial, 171t, 172-173
  - premature, lipid disorders in, 59-61, 60-61t, 60t
  - risk, hypertriglyceridemias and, 42
- CAIUS (Carotid Atherosclerosis Italian Ultrasound Study), 149, 150t, 194t
- Calcium, scan of coronary arteries for, 107, 110t, 129
- Calculate component (ACT/treatment algorithm), 378-380, 379t
- Caloric intake
- excess, 221-224, 343-344
  - recommended, 212t
- Canadian Coronary Atherosclerosis Intervention Trial. See *CCAIT*.
- Canola oil, 218, 228t
- Carbamazepine, 88
- Cardioprotective Dietary Study (India), 202
- Cardiovascular disease. See *CVD*.
- Cardiovascular drugs, 82-84, 82
- CARDS (Collaborative Atorvastatin Diabetes Study), 176t-177t, 182, 190t, 298
- CARE (Cholesterol and Recurrent Events) trial, 161, 166t, 178, 336
- Carotenoids, 230-231

- Carotid artery disease, 378  
 cIMT measurement, 193-199, 194t-195t, 200t, 329-330, 336  
 clinical tip, 196  
 lipid-lowering trials and, 193-199, 194t-195t, 198t, 200t  
 Carotid Atherosclerosis Italian Ultrasound Study. See *CAIUS*.  
 Carvedilol, 83  
 CASS (Coronary Artery Study), 340  
 CCAIT (Canadian Coronary Atherosclerosis Intervention Trial), 144, 146, 147, 148t, 336  
 CDP (Coronary Drug Project), 165-172, 166t, 296, 300-301, 363  
 Celiac disease, 71, 89  
 Cerivastatin, 273  
 CETP (cholesterol ester transfer protein), 29-30  
 HDL/HDL-c levels and, 34, 118  
 in hypertriglyceridemias, 44  
 inhibitor of (torcetrapib), 34, 119, 197-199, 198t  
 CHD (coronary heart disease). See also *Atherosclerosis and acute coronary syndromes*; *CVD (cardiovascular disease)*.  
 cholesterol-lowering therapy and, 15  
 equivalents (risk equivalents), 101, 378  
 familial, lipid disorders in, 59  
 family screening and, 58  
 Framingham risk projections, 16t  
 frequency of dyslipidemia syndromes in coronary-prone families, 58t  
 HDL/HDL-c levels and, 32t-33t, 33-34, 117-118  
 L-TAP and, 20t  
 premature  
 in autosomal recessive hypercholesterolemia, 40  
 familial hypercholesterolemia and, 62-63  
 in familial hyperlipidemia, 53, 66  
 family history of, 102t, 377  
 HDL-c deficiencies and, 58  
 lipid disorders in, 59-61, 60-61, 60t  
 risk, 101-119, 102t, 116t, 120t  
 abnormal LDL levels and, 56  
 ADA/ACC consensus statement on, 120t  
 age and, 102t, 104t-107t  
 apo B as predictor of, 100  
 criteria, 379t  
 diabetes and, 356-357, 357  
 downloadable spreadsheet for calculating, 102  
 elderly and, 340-343  
 equivalents, 101, 378  
 familial combined hyperlipidemia and, 38, 66  
 familial defective apo B-100 and, 39  
 familial dysbetalipoproteinemia and, 69  
 familial hypertriglyceridemia and, 69  
 hyperlipoproteinemias and, 23  
 hypertriglyceridemias and, 42-43, 45  
 insulin resistance and, 351-353, 352t  
 LDL phenotype B and, 68  
 Lp(a) and, 63, 72, 86  
 medications, potential increase in risk from, 81  
 non-HDL-c as predictor of, 101  
 obesity and, 15-16, 344-346, 345t  
 overall evaluation of, 165  
 CHD (coronary heart disease), risk (*continued*)  
 status and goals, treatment algorithm, 377-378, 379t  
 women and, 331-340  
 small, dense LDL particles and, 32-33, 32t  
 treatment algorithm and, 378  
 Chicago Heart Association Detection Project, 128t  
 Children, 325-331  
 CHD/CVD risk, 325-329  
 classification of cholesterol levels in, 326t  
 clinical tips, 325-326, 327, 328, 331  
 diet and TLC for, 326-327  
 drug therapy for, 328, 329-331  
 goals of therapy, 326t  
 NCEP recommendations on, 325-326  
 Chlorthalidone, 83  
 Cholestasis, 89, 91  
 Cholesterol. See also *HDL-c*; *Hypercholesterolemia*; *LDL-c*; *Non-HDL-c*  
 cardiovascular drugs and, 82-83, 82  
 dietary, 212t, 214-215  
 LDL as carrier for, 25  
 levels. See also *HDL-c*; *LDL-c*.  
 in familial lipid disorders, 62-75  
 hyperlipoproteinemias and, 23  
 as risk factor, 14, 14t  
 non-HDL, 57  
 Cholesterol absorption inhibitor. See *Ezetimibe*.  
 Cholesterol and Recurrent Events trial. See *CARE trial*.  
 Cholesterol ester transfer protein. See *CETP*.  
 Cholesterol Lowering Atherosclerosis Study I and II. See *CLAS-I and CLAS-II*.  
 Cholesterol Treatment Trialists Collaborators. See *CTT*.  
 Cholestyramine, 146, 276. See also *Bile acid sequestrants*.  
 adverse effects, 282-283  
 clinical trials, 171t, 177t  
 in combination therapy, 306  
 cost, 278t, 284  
 hints to improve compliance, 283  
 preparations and dosing regimen, 258t, 277  
 Chylomicronemia, 55t, 72-75, 73t  
 classification, 73  
 diabetes and, 90  
 Chylomicrons, 25-26. See also *Chylomicronemia*.  
 in classification of hypertriglyceridemia, 73  
 composition and size, 24t  
 function of, 23  
 genesis and fate of, 25-26  
 pancreatitis and, 35  
 Cigar smoking, 88  
 Cigarette smoking, 62, 80t, 88, 346  
 as CHD risk factor, 102t, 104t, 106t, 327, 333, 377  
 Cimetidine, 88  
 CLAS-I and CLAS-II (Cholesterol Lowering Atherosclerosis Study I and II), 157, 162t, 183, 283  
 Classifications  
 familial hyperlipidemia, 53-77  
 lipoproteins, 23-25, 24t, 53-55, 53t  
 Clinical appraisal and therapy goals, 99-122  
 apo B, 119, 120t

Clinical appraisal and therapy goals (*continued*)

clinical tips for, 101, 102, 107, 114, 116  
diet and TLC, 108t-109t, 110  
drug therapy initiation and, 108t-109t, 110  
lipid data/measurement options, 56  
lipid screening, 99-101  
low HDL treatments, 117-119  
metabolic syndrome and, 110-112, 111t, 113  
NCEP screening recommendations, 99-101  
risk

10-year CHD risk assessment, 102, 104t-107t, 378  
ADA/ACC consensus statement on, 120t  
categories, 20t, 102-107, 108t-109t  
  highest risk, 103, 108t-109t  
  lower risk, 105-107, 108t-109t  
  moderate risk, 103, 108t-109t  
  moderately high risk, 103, 108t-109t  
CHD equivalents, 101  
comparison of LDL-c and non-HDL-c goals, 116t  
emerging risk factors, 107, 110t, 112  
Framingham risk scores, 104t-107t  
high risk identification, 101  
major risk factors, 101-102, 102t  
of near-term coronary event, 101  
overall evaluation of, 165  
TLC initiation and, 108t-109t, 110  
triglyceride therapy and, 113-117, 115t, 116t

Clinical tips. See also *specific topics*.

for acute coronary syndromes and atherosclerosis, 126  
for clinical appraisal and therapy goals, 101, 102, 107, 114, 116  
for diet and TLC, 218, 233, 237  
for elderly patients, 341-342, 343  
for exercise and metabolic syndrome, 250, 251  
for treatment algorithm, 377  
for women, 332-333, 338

Clinical trials and research studies, 132-138, 143-210. See also *Clinical trials and research studies: specific trials and studies*.

angiographic trials, 143-146, 144, 157-160  
  double-drug trials, 157-160, 162t-163t  
  monotherapy trials, 143-146  
  multiple intervention trials, 157-160, 164t  
  resin trials, 145t  
carotid artery studies, 193-199, 194t-195t, 198t, 200t  
diet and TLC, 159, 164t, 179-180  
HMG-CoA reductase inhibitor (statins) trials, 132-138, 146-157  
  atorvastatin, 132-133, 133t, 135t, 151-155, 154t  
  fluvastatin, 144, 151, 153t  
  lovastatin, 144, 146-147, 148t  
  pravastatin, 133t, 136-137, 149, 150t  
  rosuvastatin, 138, 155-156  
  simvastatin, 133t, 135t, 137-138, 144, 149-151, 152t, 160-161  
IVUS trials, 155-156  
large-scale trials, 160-199  
  apheresis trials, 182-183, 184t  
  carotid artery disease and lipid-lowering trials, 193-199, 194t-195t, 198t, 200t  
  LDL-c-lowering trials (hypertensive and diabetic subject focus), 180-182  
  lipid drugs in diabetic trials, 188-193, 190t-192t

Clinical trials and research studies, large-scale trials (*continued*)

  non-LDL-lowering trials, 183-188, 186t-187t  
  primary prevention trials, 174-180, 176t-177t  
  secondary prevention trials, 160-174, 166t-170t  
  meta-analysis of, 174  
  partial ileal bypass trials, 156-157, 158t  
  post-coronary artery bypass, 171t, 172-173  
  vitamins and supplements, 157, 159-160, 162t-163t  
Clinical trials and research studies: specific trials and studies  
A-Z trial (Phase Z), 133t, 137-138, 168t  
ACAPS, 147, 148t, 149, 194t  
ACCORD trial, 189-193, 299, 361  
ADMIT, 291-292  
ADVANCE trial, 361  
AFCAPS/TexCAPS, 15, 100, 132, 175, 176t, 335  
ALLHAT-LLA, 176t, 181  
ARBITER and ARBITER-2, 194t  
ASAP trial, 194t  
ASCOT-LLA, 175-179, 176t, 181-182, 193, 342  
ASTEROID trial, 155-156  
BECAIT, 183-185, 186t, 296  
BHAT, 83  
BIP, 185-188, 186t, 296  
Bogalusa Heart Study, 331  
CAIUS, 149, 150t, 194t  
Cardioprotective Dietary Study (India), 202  
CARDS, 176t-177t, 182, 190t, 298  
CARE trial, 161, 166t, 178, 336  
CASS, 340  
CCAIT, 144, 146, 147, 148t, 336  
CDP, 165-172, 166t, 296, 300-301, 363  
CLAS-I and CLAS-II, 157, 162t, 283  
CTT, 266, 364  
DAIS, 186t, 189, 296, 297, 299, 300, 362  
DART, 226, 228t  
DCCT, 358-359  
Diabetes Prevention Program/Study, 248, 250t  
DISC, 326-327  
ENHANCE, 197, 199, 200t, 286  
EXCEL Study, 269  
FATS, 72, 144, 157-159, 162t, 283  
FHRS, 184t  
FIELD study, 189, 190t-191t, 296, 297-298, 299, 300, 308, 362  
Finnish Diabetes Prevention Study, 248, 249t  
4S, 132, 160-161, 166t, 268  
Framingham data, 16t  
Framingham Offspring Study, 59, 60-61  
GISSI, 227, 228t  
HARP, 144, 159, 162t  
Harvard Fish Oil Angiographic Study, 229t  
HATS, 159-160, 163t  
Heidelberg study, 164t  
HERS, 86, 336-337  
HHT, 174-175, 177t, 296, 298  
HOPE 2 trial, 234t  
HPS, 161-165, 166t-167t, 180-181, 191t, 193, 340  
IDEAL trial, 169t, 173-174

Clinical trials and research studies: specific trials and studies (*continued*)

ILLUSTRATE trial, 197  
 Indian Experiment of Infarct Survival, 229t  
 IVUS, 155-156  
 JELIS, 179-180  
 KAPS, 149, 150t, 194t  
 LAARS, 182-183, 184t, 194t  
 LCAS, 144, 151, 153t, 283, 336  
 Lifestyle Heart Trial, 164t  
 Lipid Research Clinics Follow-up Study, 331-332  
 Lipid Research Clinics Prevalence Study, 347-348  
 LIPID trial, 132, 161, 167t, 194t, 336  
 LOCAT, 185, 186t, 296  
 LRC-CPPT, 174-175, 177t, 281, 281t, 282-283  
 LUNAR trial, 138  
 Lyon Diet Heart Study, 226-227, 228t  
 MAAS, 144, 149-151, 152t  
 MARS, 144, 146-147, 148t, 149, 195t  
 MED-PED-FH, 64  
 Mediterranean Diet Study, 206  
 MEGA, 179  
 METEOR, 195t  
 MIRACL trial, 132-133, 133t  
 MRC/BHF, 206  
 MRFIT, 14, 14t, 128t  
 Multinational trial (Pravastatin), 150t  
 NHANES, 15, 343, 344-345, 344t  
 NHANES II, 348, 348, 357-358, 358  
 NHLBI Family Heart Study, 38, 45, 69, 83, 183  
 NHLBI Type II Coronary Intervention Study, 283  
 NORVIT trial, 234t-235t  
 Nurses' Health Study, 242, 345t, 347, 356  
 PDAY study, 124-126, 126, 344-345, 345-346  
 PEPI trial, 84, 85t, 337  
 PLAC-I, 150t  
 PLAC-II, 149, 150t, 195t  
 POSCH trial, 156-157, 158t  
 Post-CABG trial, 171t, 172-173  
 PROSPER trial, 167t, 174, 193, 340-342  
 PROVE-IT-TIMI trial, 266  
 PROVE-IT trial, 133t, 135t, 136-137, 167t, 173  
 RADIANCE-1, 197, 198t  
 Rancho Bernardo Study, 242  
 REGRESS, 144, 150t, 195t  
 REVERSAL trial, 151-155, 154t  
 SAFARI trial, 308  
 SANDS trial, 196-197  
 SCRIP, 160, 164t  
 STARS, 146, 283  
 Stockholm Ischemic Heart Disease Study, 289  
 STOP-Hypertension, 340  
 STRRIDE trial, 248-250, 249t  
 Study on Prevention of Coronary Atherosclerosis by Intervention with Marine  
   Omega-3 Fatty Acids, 229t  
 TNT trial, 168t-169t, 173-174  
 TOMHS, 83  
 UCSF-SCOR trials, 159, 163t

Clinical trials and research studies: specific trials and studies (*continued*)

UKPDS trial, 182  
 VA-HIT, 185-189, 187t, 191t-192t, 296, 297, 298-299, 362  
 WHI trial, 85, 223-224  
 WHO Clofibrate Trial, 296  
 WOSCOPS, 175, 177t, 178, 364  
 Clofibrate. See also *Fibric acid derivatives*.  
   clinical trials, 165-172, 296  
   dosing, 294t  
   metabolism and excretion, 296  
 Clomiphene, 86  
 Clozapine, 88  
 Coenzyme A, 260  
 Coffee, 221  
 Colesevelam. See also *Bile acid sequestrants*.  
   adverse effects, 282-283  
   in combination therapy, 306  
   cost, 278t, 284  
   indications for, 277  
   preparations and dosing regimen, 258t, 277  
   tolerability, 283  
   use in diabetes, 277, 363  
 Colestid, 276. See also *Colestipol*.  
   cost, 278t  
   preparations and dosing regimen, 258t  
 Colestipol, 276. See also *Bile acid sequestrants*.  
   adverse effects, 282-283  
   clinical trials with, 157, 162t-163t  
   in combination therapy, 306  
   cost, 278t, 284  
   hints to improve compliance, 283  
   preparations and dosing regimen, 258t  
 Collaborative Atorvastatin Diabetes Study. See *CARDS*.  
 Combination drug therapy, 303-308. See also *specific drugs and drug classes*.  
   for bile acid sequestrant use in hypertriglyceridemic patients with  
     high LDL-c, 307  
   clinical tip, 306  
   cost of, 279t, 308  
   in diabetic patients, 364  
   to maximize doses and side effects, 306  
   to maximize LDL-c reduction, 304-306, 304t  
   to maximize VLDL reduction, 306  
   preparations and dosing regimens, 259t  
   reasons for use, 303-304, 304t  
   to treat combined hyperlipidemia and metabolic syndrome, 307-308  
 Combined hyperlipidemia. See *Familial combined hyperlipidemia*.  
 Computed tomography (CT), 107, 110t  
 Contraceptives, oral, 86  
 Coronary artery bypass, post-bypass trial (Post-CABG), 171t, 172-173  
 Coronary artery disease. See *CAD (coronary artery disease)*.  
 Coronary Artery Study. See *CASS*.  
 Coronary atherosclerosis. See *Atherosclerosis and acute coronary syndromes*.  
 Coronary Drug Project. See *CDP*.  
 Coronary heart disease. See *CHD*.  
 Cost of lipid-lowering drugs, 276, 278t-279t  
 Creatine kinase (CK), 269, 270-271, 342

Crestor, 256. See also *Rosuvastatin*.  
 cost, 279t  
 preparations and dosing regimens, 259t  
 CRP. See *C-reactive protein*.  
 CsA (cyclosporine A). See *Cyclosporine*.  
 CT. See *Computed tomography (CT)*.  
 CTT (Cholesterol Treatment Trialists) Collaborators/statin trials, 266, 364  
 CVD (cardiovascular disease). See also *CHD (coronary heart disease)*.  
 in children and adolescents, 325-329  
 in elderly patients, 340-343  
 family history of, 325  
 mortality from 340  
 in women, risk of, 331-340, 334t  
 Cyclosporine, 80t, 87, 93  
 CsA (cyclosporine A), 93, 271-272  
 drug interactions, 274, 274t  
 CYP3A4, 262  
 Cytokines, 349

D (four D's mnemonic: diet, drugs, disorders of metabolism, diseases), 79  
 DAIS (Diabetes Atherosclerosis Intervention Study), 186t, 189, 296, 297, 299, 300, 362  
 DART (Diet and Reinfarction Trial), 226, 228t  
 Data sheet for assembling data, 381, 382  
 DCCT (Diabetes Control and Complications Trial), 358-359  
 Defective apo B, 36t, 38-39, 55t  
 Desogestrel, 85  
 DHA (docosahexaenoic acid), 225-226, 227, 301-303  
 Diabetes, 69, 356-364, 378  
 bile acid sequestrants, effects on glycemic control, 281-282  
 CHD mortality and, 356-357, 357  
 CHD risk equivalent, 101  
 clinical trials, 180-182, 188-193, 190t-192t, 356-362  
 coronary risk and, 356-357, 357  
 in elderly patients, 342  
 global risk score, downloadable calculator for, 182  
 hypertension in, carvedilol use for, 83  
 LDL glycosylation and, 359-360, 359t  
 lipoprotein disorders in, 56, 357-360, 358, 358t  
 as secondary cause of dyslipidemia, 80t, 90  
 treatment of lipid disorders in, 360-364  
 in women, 336  
 Diabetes Atherosclerosis Intervention Study. See *DAIS*.  
 Diabetes Control and Complications Trial. See *DCCT*.  
 Diabetes Prevention Program/Study, 248, 250t  
 Diagnosis, 55t, 58, 58t, 65, 65t  
 Dialysis, renal, 80t  
 Diet, as secondary cause of dyslipidemia, 79-81, 80t  
 Diet and Reinfarction Trial. See *DART*.  
 Diet and TLC (Therapeutic Lifestyle Change), 16, 81, 211-240  
 clinical appraisal, 108t-109t, 110  
 clinical tips for, 218, 233, 237  
 clinical trials and research studies of, 160, 164t  
 in Asian populations, 179-180  
 counseling to improve adherence, 236-237  
 diet, as secondary cause of dyslipidemia, 79-81, 80t  
 diet counseling tips, 217, 219, 220, 221, 222, 224, 225, 227, 231, 233-237

Diet and TLC (Therapeutic Lifestyle Change) (*continued*)  
 dietary-lipid/lipoprotein influences, 214-220  
 dietary cholesterol, 214-215  
 dietary fiber, 219-220  
 low-fat high-carbohydrate diets, 219  
 monounsaturated fats (MUFAs), 218-219  
 polyunsaturated fats (PUFAs), 217-218  
 saturated fats, 215-217, 216t  
 trans fatty acids (TFAs), 217  
 vegetable protein, 220  
 exercise and metabolic syndrome. See *Exercise, lipids, and metabolic syndrome*.  
 LDL-c levels for initiation of, 108t-109t  
 multiple risk factors and, 16t  
 NCEP/ATP III recommendations for, 211-213, 212t  
 other dietary factors, 221-237  
 alcohol, 80t, 224-225  
 antioxidants, 230-231  
 Atkins diet, 222-224, 223  
 coffee, 221  
 DIET CAGE Questionnaire, 236t  
 EPA, 179-180  
 excess caloric intake, 221-224  
 fish oils and fish intake, 80t, 180, 225-227, 228t-229t  
 folic acid, 232-233, 234t-235t  
 garlic, 221  
 homocysteine [H(e)], 232-233, 234t-235t  
 low-fat diet, 80t, 160, 164t, 179, 219  
 Mediterranean style diets, 226-227  
 MUFAs, 212t, 218-219  
 omega 3 fatty acids, 180  
 Ornish diet, 222-224, 223  
 PUFAs, 212t, 217-218, 225-227  
 Step I and Step II Diets, 211, 326  
 vegetarian diets, 233-237  
 vitamins B6 and B, 232-233, 234t-235t  
 Weight Watchers diet, 222-224, 223  
 Zone diet, 222-224, 223

DIET CAGE Questionnaire, 236t  
 Dietary Intervention Study on Children. See *DISC*.  
 Digoxin, 276  
 DISC (Dietary Intervention Study on Children), 326-327  
 Diseases, as secondary cause of dyslipidemia, 80t, 91-92  
 Disorders of metabolism, as secondary cause of dyslipidemia, 80t, 89-91  
 Diuretics, 80t, 82-83, 82  
 Docosahexaenoic acid. See *DHA*.  
 Doxazosin, 83  
 Drug interactions. See also *specific drugs*.  
 bile acid sequestrants, 274t, 283-284  
 fibric acid derivatives, 299-301, 299t  
 HMG-CoA reductase inhibitors (statins), 271-272, 274-276, 275t, 300  
 nicotinic acid (niacin), 274, 274t  
 Drugs and drug therapies, 255-323. See also *Diet and TLC (Therapeutic Lifestyle Change); specific drugs and drug classes*.  
 bile acid sequestrants, 276-284  
 cardiovascular drugs, 82-84, 82  
 combination drug therapy, 303-308

Drugs and drug therapies (*continued*)

- cost of, 278t-279t
  - efficacy of. See *Efficacy of drug therapies.*
  - endocrine drugs, 84-86, 85t
  - HMG-CoA reductase inhibitors (statins), 255-276
  - lipid-lowering drugs, 255-323
  - n-3 fatty acids and fish oils, 301-303
  - other frequently used drugs, 86-89
  - as secondary cause of dyslipidemia, 80t, 81-89
- Dysbetalipoproteinemia, familial (type III hyperlipoproteinemia), 41-45, 41t, 55t, 69
- fibrates as drugs of choice for, 299
  - obesity and, 347
- Dyslipidemic hypertension, familial, 58t, 67-68
- EBCT (electron-beam computed tomography), 336
- Education level, success in lipid lowering programs and, 21
- Efficacy of drug therapies
- bile acid sequestrants, 281-282, 281t
  - cholesterol absorption inhibitor (ezetimibe), 286
  - fibric acid derivatives, 256t, 293-295
  - HMG-CoA reductase inhibitors (statins), 262-268, 264t
  - nicotinic acid (niacin), 289
- Eicosapentaenoic acid (EPA), 179-180, 225-226, 227, 301-303
- Elderly patients, 340-343
- attributable risk, 340-341
  - CHD/CVD and, 340-343
  - clinical tips, 341-342, 343
  - clinical trials, 167t, 174, 193, 340-343
  - Framingham risk scores, 341-342
  - secondary causes of high cholesterol and, 342
  - statins and, 342
- Electron-beam computed tomography (EBCT), 336
- Electrophoretic markers/patterns, lipoprotein, 24t, 53-54, 54t, 68
- Emerging risk factors, 107, 110t, 112, 129
- ENHANCE (Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression), 197, 199, 200t, 286
- EPA (eicosapentaenoic acid), 179-180, 225-226, 227, 301-303
- Eruptive xanthomas. See *Xanthomas.*
- Erythromycin, drug interactions, 274, 274t
- Estrogens
- formulations, 84-85, 85t
  - hormone therapy in women, 332-333, 337, 339
  - lipid levels and, 84-85, 85t, 331-333, 332
  - LP(a) levels and, 32
  - oral contraceptives, 333
  - pancreatitis risk and, 81
  - as secondary cause of dyslipidemias, 80t
  - stroke and, 85, 332
  - transdermal estrogen patches, 332-333
- EXCEL (Expanded Clinical Evaluation of Lovastatin) Study, 269
- Exercise, lipids, and metabolic syndrome, 15, 241-254
- AHA recommendations, 247-248
  - ATP III and, 241
  - cardiovascular events, exercise and, 241-242
  - clinical tips for, 250, 251
  - clinical trials and research studies, 248-251, 249t

- College of Sports Medicine recommendations, 247-248
  - exercise prescription, 245-248, 246t
  - lipid level changes, magnitude of, with exercise, 243-245, 244t
  - lipids, exercise and, 242-243, 244t
  - NCEP and, 241
  - percentage of adults reporting common exercise, 247t
  - postprandial lipid changes, 243, 244t
  - practical considerations for exercise, 245-248, 246t
  - Surgeon General's Report on Physical activity, 245-247
  - TLC and, 248-251, 249t
- Expanded Clinical Evaluation of Lovastatin Study. See *EXCEL.*
- Eye drops, timolol, 88
- Ezetimibe, 284-287
- adverse events, 286-287
  - clinical trials, 197, 199, 200t, 286
  - in combination therapy
    - doses and side effects in, 306
    - ezetimibe/bile acid sequestrants, 304t, 305
    - ezetimibe/nicotinic acid, 305
    - ezetimibe/simvastatin, 259t, 279t
    - ezetimibe/statins, 304t, 305, 306
  - cost, 278t, 287
  - cyclosporine and, increase in concentration by, 87
  - efficacy, 286
  - mechanism of action and metabolism, 256t, 284-286
  - preparations and dosing regimen, 258t

Factor V Leiden, 337

Familial Atherosclerosis Treatment Study. See *FATS.*

Familial CHD, lipid disorders in, 59

Familial combined hyperlipidemia (FCHL), 36-38, 36t, 55t, 66-67

CHD and, 58t, 66

in children, drug therapy for, 328, 329-331

description of, 66-67

hyperinsulinism and, 67

statin-fibrate combination therapy for, 307-308

vs familial hypercholesterolemia (FH), 66-67, 67t

vs nephrotic syndrome, 92

Familial defective apo B-100, 36t, 38-39, 55t

Familial dysbetalipoproteinemia (familial type III hyperlipoproteinemia),

41-42, 41t, 55t, 69

fibrates as drugs of choice for, 299

obesity and, 347

Familial dyslipidemic hypertension, 58t, 67-68

Familial hypercholesterolemia (FH), 35-36, 36t, 55t, 62-65, 159

apheresis for, 183

atorvastatin vs simvastatin in, 196

causes of, 35-36, 62

CHD and frequency of, 58t

described, 62-65

heterozygous

diagnosis of, 65, 65t

LDL-c level for initiation of TLC in, 105

prognosis if untreated, 64

screening and, 64

symptoms, 62-63

vs familial combined hyperlipidemia (FCHL), 66-67, 67t

- Familial Hypercholesterolemia Regression Study. See *FHRS*.
- Familial hyperchylomicronemia, 72-75, 73, 73t
- Familial hyperlipidemia. See *Hyperlipidemia, familial*.
- Familial hypertriglyceridemia, 44-45, 55t, 69-71
- Familial hypoalphalipoproteinemia, 55t, 71
- Familial lipid disorders, 62-75. See also *Genetic conditions leading to LDL elevation; specific disorders*.
- with high cholesterol due to excess LDL-c, 62-66
    - familial defective apolipoprotein B hyperlipoproteinemia, 36t, 38-39, 55t
    - familial hypercholesterolemia, 62-65
    - primary polygenic LDL excess, 66
  - with low levels of HDL-c or elevated Lp(a), 71-72
    - familial hypoalphalipoproteinemia, 55t, 71
    - Lp(a) excess, 55t, 71-72
  - with mild-to-moderate triglyceride excess, 66-71
    - familial combined hyperlipidemia, 66-67
    - familial dysbetalipoproteinemia (a/k/a familial type III), 41-42, 41t, 55t, 69
    - familial dyslipidemic hypertension, 58t, 67-68
    - familial hypertriglyceridemia, 69-71
    - LDL phenotype B (small, dense LDL), 68
      - resulting in severe hypertriglyceridemia (chylomicronemia), 72-75
- Familial lipoprotein lipase deficiency, 55t, 72-75
- Familial type III hyperlipoproteinemia, 41-42, 41t, 58t
- Family Heart Study. See *NHLBI Family Heart Study*.
- Farnesoid X receptor (FXR), 277-278
- Fasting lipoprotein panel, 99-101
- Fat-soluble vitamins, deficiencies of, 25
- FATS (Familial Atherosclerosis Treatment Study), 72, 144, 157-159, 162t, 283
- FCHL. See *Familial combined hyperlipidemia*.
- Female patients. See also *Women*.
- Fenofibrate Intervention and Event Lowering in Diabetes study. See *FIELD study*.
- Fenofibrates, 88. See also *Fibric acid derivatives*.
- clinical trials, 189, 190t-191t, 296-297
  - cost, 278t, 301
  - for diabetic patients, 362, 364
  - drug interactions, 274t
  - efficacy, 295
  - mechanism of action, 294-295
  - metabolism and excretion, 296
  - micronized, 186t, 189, 297
  - preferred in combination therapy with statins, 308, 380
  - preparations and dosing, 258t, 294t
- FH. See *Familial hypercholesterolemia*.
- FHRS (Familial Hypercholesterolemia Regression Study), 184t
- Fiber, dietary, 212t, 219-220
- Fibrates. See *Fibric acid derivatives*.
- Fibric acid derivatives, 88, 293-301. See also *specific drugs*.
- adverse effects and drug interactions, 299-301, 299t
  - clinical trials, implications of, 296-299
  - in combination therapy
    - fibric acid derivatives/bile acid sequestrants, 307
    - fibric acid derivatives/statins, 18, 304t, 307-308, 364, 380
  - cost, 278t, 301
  - for diabetic patients, 362, 363, 364
  - dosing, 294t
  - drugs in this class, 293, 294t
- Fibric acid derivatives (*continued*)
- efficacy and mechanism of action, 256t, 293-295
  - HDL-c syndromes due to, 80t, 89
  - for high triglycerides, 88, 117
  - indications for, 256t
  - for low HDL-c, 117, 118, 119
  - metabolism and excretion, 256t, 295-296
- FIELD (Fenofibrate Intervention and Event Lowering in Diabetes) study, 189, 190t-191t, 296, 297-298, 299, 300, 308, 362
- Finnish Diabetes Prevention Study, 248, 249t
- Fish oils, 301-303
- adverse effects, 303
  - clinical tip, 303
  - cost, 279t, 303
  - fish intake (dietary) and, 180, 225-227, 228t-229t
  - mechanism of action, 256t, 302-303
  - as secondary cause of dyslipidemia, 80t
- Flushing, cutaneous, 290, 292-293
- Fluvastatin, 255
- cost, 278t
  - drug interactions, 274, 274t, 284
  - efficacy, 264t
  - mechanism of action, 256
  - metabolic parameters, 260-262, 261t
  - preparations and dosing regimens, 259t
- Focal coronary atherosclerosis. See *Atherosclerosis and acute coronary syndromes*.
- Folic acid, 232-233, 234t-235t, 339
- Four D's mnemonic, 79
- 4S (Scandinavian Simvastatin Survival Study), 132, 160-161, 166t, 268
- Framingham data, CHD risk and, 16t
- Framingham Offspring Study, 59, 60-61
- Framingham Risk Assessment tool, 19
- Framingham risk scores
- for men, 104t-105t, 335t
  - for women, 106t-107t, 335t
- Frederickson, Donald, 53
- Friedewald formula, 99-100
- FXR (farnesoid X receptor), 277-278
- G-protein-coupled receptor, 287-288, 290
- Gallstone disease, 299, 299t
- Garlic, 221
- Gemfibrozil, 118. See also *Fibric acid derivatives*.
- clinical trials, 177t, 185, 191t-192t, 296-297
  - contraindications/precautions, 307-308
  - cost, 278t, 301
  - drug interactions, 274, 274t
  - efficacy, 295
  - metabolism and excretion, 296
  - preparations and dosing, 258t, 294t
  - statins with, 271
- Genetic conditions leading to LDL elevation, 35-41, 36t, 55t.
- See also *specific conditions*.
  - autosomal recessive hypercholesterolemia, 36t, 40
  - beta sitosterolemia, 36t, 40-41
  - familial combined hyperlipidemia, 36-38, 36t

- Genetic conditions leading to LDL elevation (*continued*)  
 familial defective apo B-100, 36t, 38-39, 55t  
 familial hypercholesterolemia, 35-36, 36t  
 familial hyperlipidemia. See *Hyperlipidemia, familial*.  
 gain of function mutations of protease PCSK9, 36t, 39  
 ranked by predominant lipid abnormality, 55t  
 severe primary polygenic elevation of LDL, 36t, 39-40
- Genetic diagnosis, 55t, 58, 58t
- Geranylgeranyl pyrophosphate, 268
- Geriatric patients. See *Elderly patients*.
- Gestodene, 85
- GGE (gradient gel electrophoresis), 56
- GISSI (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico Prevenzione) trial, 227, 228t
- Glucocorticoids, 80t, 84
- Goals (therapy). See *Clinical appraisal and therapy goals; Treatment algorithm*.
- GPR109A, 287-288, 290
- Gradient gel electrophoresis (GGE), LDL and HDL segmented, 56
- Grapefruit juice, statins and, 274
- Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico (GISSI) Prevenzione trial. See *GISSI*.
- HARP (Harvard Atherosclerosis Reversibility Project), 144, 159, 162t
- Harvard Atherosclerosis Reversibility Project. See *HARP*.
- Harvard Fish Oil Angiographic Study, 229t
- HATS (HDL-Atherosclerosis Treatment Study), 159-160, 163t
- HDL (high-density lipoprotein), 28-29  
 anti-inflammatory properties, 33-34  
 atherogenesis and, 32t-33t, 33-34  
 clinical appraisal and, 117-119  
 clinical trials (VA-HIT), 118, 185-188, 187t, 191t-192t  
 composition and size, 24t, 25  
 formation, 28t  
 interactions, 29-30  
 levels  
   CETP and, 34  
   CHD risk and, 32t-33t, 33-34, 117-118  
   critical illness and, 89  
   drugs and, 88-89  
   increased, 33-34  
   insulin resistance and, 354t, 355  
   low  
     disorders associated with, 55t, 71  
     treatments, 117-119  
   as marker for abnormality of other lipoproteins, 33  
   obesity and, 347t, 348-349, 348  
   metabolism, 28-29  
   in treatment algorithm, 377
- HDL-c (high-density lipoprotein cholesterol)  
 bile acid sequestrants and, 281-282  
 in CAD patients, 61  
 fibric acid derivatives and, 80t, 89  
 low levels  
   in familial hypoalphalipoproteinemia, 71  
   frequency of in CHD-prone families, 58t  
   as major risk factor, 102t, 118  
   nicotinic acid as first-line drug for, 287, 288
- HDL-c (high-density lipoprotein cholesterol) (*continued*)  
 oral contraceptives and, 86  
 population distribution of, 46t  
 risk factor level, 14
- H(e). See *Homocysteine*.
- Heart and Estrogen/Progestin Replacement Study,  
 African American women on, 21
- Heart and Estrogen Replacement Study (HERS), 86
- Heart Outcomes Prevention Evaluation 2 trial. See *HOPE 2 trial*.
- Heart Protection Study. See *HPS*.
- Heidelberg study, 164t
- Helsinki Heart Trial. See *HHT (Helsinki Heart Trial)*.
- Hepatitis, 291
- Hepatosplenomegaly, 74
- Hepatotoxicity  
 nicotinic acid and, 291  
 statins and, 269, 269t
- HERS (Heart and Estrogen Replacement Study), 86, 336-337
- HHT (Helsinki Heart Trial), 174-175, 177t, 296, 298
- High-density lipoprotein (HDL). See *HDL and HDL-c*.
- Historical overview, 13-18
- HIV (human immunodeficiency virus) infection, 87-88
- HMG-CoA reductase inhibitors (statins), 255-276. See also *specific drugs*.  
 adverse effects, 268-273, 269t  
 anti-inflammatory effects of, 266-267  
 benefits other than lipid-lowering, 267-268  
 clinical trials of, 18, 132-138, 146-157, 266-268  
 combination therapy. See *Statins, in combination therapy*.  
 cost, 276, 278t-279t  
 dose-response curve, 276, 280  
 drug interactions, 271-272, 274-276, 275t, 300  
 drugs in this class, 255-256  
 efficacy—clinical and atherosclerosis end points, 266-268  
 efficacy—lipid effects, 262-265, 264t  
 indications for, 256t  
 mechanism of action and drug metabolism, 256-262, 256t, 257t  
 preparations and dosing regimens, 259t  
 selection of, 263-265
- Homocysteine [H(e)], 110t, 232-233, 234t-235t
- HOPE 2 (Heart Outcomes Prevention Evaluation 2) trial, 234t
- Hormone replacement therapies, 332-333, 337, 339
- Hormone-sensitive lipase (HSL), 355
- HPS (Heart Protection Study), 161-165, 166t-167t, 180-181, 191t, 193, 340
- Human immunodeficiency virus (HIV) infection, 87-88
- Hypercholesterolemia  
 autosomal dominant (mutations of PCSK9), 36t, 39  
 autosomal recessive, 36t, 40  
 familial, 35-36, 36t, 55t, 62-65, 159
- Hyperinsulinemia, 67, 351-355, 352t
- Hyperlipidemia, treating patients with, 18-19
- Hyperlipidemia, familial, 53-77. See also *Hyperlipoproteinemias*.  
 CHD and, 53, 66  
 classification of, 53-77  
 combined, 36-38, 36t  
 early recognition/treatment of, 53  
 familial lipid disorders, 35-41, 36t, 62-75. See also *Familial lipid disorders*.  
 familial combined hyperlipidemia (FCHL), 36-38, 36t, 55t, 66-67

Hyperlipidemia, familial; familial lipid disorders (*continued*)

familial defective apo B-100, 36t, 38-39, 55t  
familial defective apo B hyperlipoproteinemia, 36t, 38-39, 55t  
familial dysbetalipoproteinemia (familial type III), 41-42, 41t  
familial dyslipidemic hypertension, 58t, 67-68  
familial hypercholesterolemia, 35-36, 36t  
familial hypercholesterolemia (FH), 35-36, 36t, 55t, 62-65, 159  
familial hypertriglyceridemia, 44-45, 55t, 69-71  
familial hypoalphalipoproteinemia, 45, 55t, 71  
primary polygenic LDL elevation, 36t, 39-40, 55t, 66  
severe hypertriglyceridemia, 34-35, 69-71  
genetic diagnoses and, 55t, 58, 58t

Hyperlipoproteinemias, 23-51. See also *specific topics*.

apolipoproteins and, 23-25  
atherogenesis and, 30-34, 31t-33t  
cholesterol ester transfer protein (CETP) and, 29-30  
chylomicrons and, 25-26  
genetic conditions leading to, 35-41, 36t  
HDLs and, 28-29, 28t, 33-34, 33t  
hypertriglyceridemias, 42-45  
hypoalphalipoproteinemia, 45  
IDL elevation (Type III hyperlipoproteinemia), 41-42, 41t  
LDL, genesis and fate of, 27-28  
LDL elevations, primary, pathogenesis of, 35-41, 36t  
lipoproteins in disease, 30-35  
normal lipoprotein metabolism, 23-30  
pancreatitis and, 34-35  
pathophysiology of, 23-51  
plasma lipoproteins and apolipoproteins, 23-25, 24t  
secondary, 79-97, 80t. See also *Secondary hyperlipoproteinemias*.  
diet and, 79-81, 80t  
diseases and, 80t, 89-92  
disorders of metabolism and, 80t, 89-91  
drugs and, 80t, 81-89  
transplantation and, 92-93  
Type I, pancreatitis and, 35  
Type III (familial dysbetalipoproteinemia), 41-42, 41t  
Type V, 35  
VLDLs and, 26-27

Hypertension

as CHD risk factor, 102t, 104t, 106t, 377  
clinical trials involving patients with, 180-182  
drug treatment of, lipids and, 82-84, 82, 380  
familial dyslipidemic, 58t, 67-68

Hypertriglyceridemias, 42-45

categorization of, 43  
familial, 44-45, 55t  
familial combined hyperlipidemia, 36-38, 36t, 55t, 66-67  
familial dysbetalipoproteinemia (familial Type III), 41-42, 41t, 55t, 69  
familial dyslipidemic hypertension, 58t, 67-68  
familial hypertriglyceridemia, 44-45, 55t, 69-71  
LDL phenotype B (small, dense LDL), 68  
nicotinic acid (niacin) as first-line drug for, 287  
pathophysiologic mechanisms, 43t, 44  
severe  
bone marrow transplantation and, 87  
CHD and pancreatitis risk and, 19, 69-71  
pancreatitis and, 34-35, 71

Hypoalphalipoproteinemia, 45, 55t, 71  
Hypothyroidism, 62, 69, 342  
as secondary cause of dyslipidemia, 80t, 89

IDEAL (Incremental Decrease in End Points in Ischemic Disease) trial, 169t, 173-174

IDL (intermediate-density lipoprotein), 27

Ileal bypass trials, 156-157, 158t, 266

ILLUSTRATE (Investigation of Lipid Level Management to Understand Its Impact In Atherosclerotic Events) trial, 197

Immunosuppressant medications, 86-87

IMT (intimal-medial thickness), carotid, 193-199, 194t-195t, 200t, 329-330

Incremental Decrease in End Points in Ischemic Disease trial. See *IDEAL trial*.

Indian Experiment of Infarct Survival, 229t

Inflammation, anti-inflammatory properties of HDL, 33-34

Insulin-resistance, 351-355

coronary risk and, 351-353, 352t

in familial combined hyperlipidemia, 38

mechanisms of effects on lipoproteins, 353-355, 354t

in obese patients, 349

Interactions. See *Drug interactions*.

Interleukin-2 therapy, 89

Intermediate-density lipoproteins (IDLs), 27

Intravascular ultrasound (IVUS)

improvements in, 156

in REVERSAL trial, 151-155

trials, 155-156

vs angiography, 63, 64

IRS-2, 353

Isotretinoin, 86-87

IVUS trials, 155-156

Japan Eicosapentaenoic acid (EPA) Lipid Interventional Study (JELIS), 179-180

Japanese clinical trials, 179-180

JELIS (Japan Eicosapentaenoic acid [EPA] Lipid Interventional Study), 179-180

KAPS (Kupio Atherosclerosis Prevention Study), 149, 150t, 194t

Kidney (renal) disease, 91-92

Kidney transplants, 93

Kupio Atherosclerosis Prevention Study. See also *KAPS*.

L-TAP (Lipid-Treatment Assessment Project), 20-21, 20t

LAARS (LDL Apheresis Atherosclerosis Regression Study), 182-183, 184t, 194t

Laboratory data, evaluation of, 18-19

Lactation and pregnancy, 80t, 90-91

Large-scale trials, 160-199. See also *Clinical trials and research studies*.

apheresis trials, 182-183, 184t

carotid artery disease and lipid-lowering trials, 193-199, 194t-195t, 198t, 200t

LDL-c-lowering trials, hypertensive and diabetic subjects, 180-182

lipid drugs in diabetic trials, 188-193, 190t-192t

non-LDL-lowering trials, 183-188, 186t-187t

primary prevention trials, 174-180

secondary prevention trials, 160-174

Laxatives, 283

LCAS (Lipoproteins in Coronary Atherosclerosis Study), 144, 151, 153t, 283, 336

LCAT. See *Lecithin cholesterol acyltransferase*.

LDL (low-density lipoprotein), 27-28. See also *LDL-c*.  
atherogenesis and, 30-33, 31t  
clearance of, 27-28, 256  
composition and size, 24t, 25  
conversion of VLDLs to, 27  
function of, 25  
genesis and fate of, 27-28  
glycosylated, in diabetes, 359-360, 359t  
interactions of, 29-30  
levels  
  CHD risk and, 23  
  genetic conditions leading to elevation of, 35-41, 36t  
  goals for, 18, 108t-109t, 116t, 378-380, 379t  
  insulin resistance and, 354t, 355  
  mechanism of benefit from lowering, 193-196  
  obesity and, 347t, 348-349, 348, 350  
  pathogenesis of primary elevations, 35-41, 36t  
  population distribution of, 37t  
  primary polygenic LDL excess, 36t, 39-40, 55t, 66  
  as target for intervention, 14  
oxidized, 30-31, 31t, 33  
Pattern A vs Pattern B, 68, 214  
receptors, 27-28  
  deficient/defective, 35-36, 36t  
  mutations in, 36t, 40  
  statins and, 256  
small, dense, 32-33, 32t, 214, 357, 358  
LDL-c (low-density lipoprotein cholesterol)  
calculating (Friedewald formula), 99-100  
clinical trials, 180-182  
excess, familial disorders associated with, 62-66  
levels  
  defined by ATP I, 14  
  distribution among adults in U.S., 37t  
  goals for, 18, 108t-109t. See also *Clinical appraisal and therapy goals*.  
  compared with non-HDL-c goals, 116t  
  high, disorders associated with, 55t  
  for initiation of drug therapy, 108t-109t  
  for initiation of TLC, 108t-109t  
  maximizing reduction of, 304-306, 304t  
  mechanism of benefit from lowering, 193-196  
  screening for, 99-101  
LDL Apheresis Atherosclerosis Regression Study. See *LAARS*.  
LDL phenotype A, 68, 214  
LDL phenotype B (small, dense LDL), 68, 214. See also *Small, dense LDL*.  
LDL receptor-like protein (LRP), 26  
Lecithin cholesterol acyltransferase (LCAT), 29, 71  
Left anterior descending (LAD) artery, 124, 126  
Lescol and Lescol XL, 255. See also *Fluvastatin*.  
  cost, 278t  
  preparations and dosing regimens, 259t  
Lifestyle Heart Trial, 164t  
Limiting Undertreatment of Lipids in ACS with Rosuvastatin (LUNAR) trial, 138  
Lipemia retinalis, 74  
Lipid Coronary Angiography Trial. See *LOCAT*.  
Lipid disorders  
  acquired causes of. See *Secondary hyperlipoproteinemias*.

Lipid disorders (*continued*)  
diagnosis of, 55t, 58, 58t  
familial, 62-75. See also *Familial lipid disorders*.  
  with high cholesterol due to excess LDL-c, 62-66  
  with low levels of HDL-c or elevated Lp(a), 71-72  
  with mild-to-moderate triglyceride excess, 66-71  
  resulting in severe hypertriglyceridemia (chylomicronemia), 72-75  
in familial CHD, 59  
  population-based frequency in coronary-prone families, 58t  
  in premature CHD, 59-61, 60t  
Lipid disorders, familial. See *Familial lipid disorders*.  
Lipid levels, disorders grouped by, 55t, 62-75  
LIPID (Long-Term Intervention With Pravastatin in Ischemic Disease) trial,  
  132, 161, 167t, 194t, 336  
Lipid-lowering drugs, 255-323. See also *specific drugs and drug classes*.  
  bile acid sequestrants, 276-284  
  combination drug therapy, 303-308  
  cost of, 278t-279t  
  dosing regimens, 258t  
  HMG-CoA reductase inhibitors (statins), 255-276  
  mechanisms of action, 255, 256t  
  n-3 fatty acids and fish oils, 301-303  
Lipid Research Clinics Coronary Primary Prevention Trial. See *LRC-CPPT*.  
Lipid Research Clinics Follow-up Study, 331-332  
Lipid Research Clinics Prevalence Study, 347-348  
Lipid screening, 99-101  
Lipid-Treatment Assessment Project. See *L-TAP*.  
Lipids Research Clinics Prevalence data, 101  
Lipitor, 255. See also *Atorvastatin*.  
  cost, 278t  
  preparations and dosing regimens, 259t  
Lipoprotein(a). See *Lp(a)*.  
Lipoprotein electrophoretic markers/patterns, 24t, 53-54, 54t, 68  
Lipoprotein lipase (LPL), 25, 294, 355  
  deficiency, familial, 55t, 72-75, 73, 73t  
Lipoprotein panel, complete, 16t  
Lipoprotein-X (Lp-X), 91  
Lipoproteins. See also *specific lipoproteins*.  
  classes of, 23-25, 24t, 53  
  diseases and, 30-35, 31t-33t  
  diseases ranked by predominant lipid abnormality, 55t  
  interactions of, 29-30  
  metabolism, normal, 23-30  
  plasma, normal, 23-25, 24t  
  typing system (I-V), 53-55, 54t  
Lipoproteins in Coronary Atherosclerosis Study. See *LCAS*.  
Liver disease, 58, 71, 91, 342  
Liver X receptors (LXRs), 26, 28, 45, 294  
LOCAT (Lipid Coronary Angiography Trial), 185, 186t, 296  
Lofibra. See also *Fenofibrates*.  
  cost, 278t, 301  
  preparations and dosing, 258t, 294t  
Long-Term Intervention With Pravastatin in Ischemic Disease trial.  
  See *LIPID trial*.  
Lopid. See also *Gemfibrozil*.  
  cost, 278t, 301  
  preparations and dosing regimen, 258t

- Lovastatin, 256  
 adverse effects, 273  
 in children/adolescents, 329  
 clinical trials, 144, 146-147, 148t, 163t, 171t  
 AFCAPS/TexCAPS, 15, 100, 132, 175, 176t, 335  
 cost, 278t  
 drug interactions, 274, 275t  
 efficacy, 264t  
 mechanism of action, 256  
 metabolic parameters, 261t, 262  
 preparations and dosing regimens, 259t  
 Lovastatin/nicotinic acid, 279t, 305-306  
 Lovaza, 279t, 303  
 Low-density lipoprotein cholesterol. See *LDL-c*.  
 Low-density lipoprotein. See *LDL*.  
 Low-fat high-carbohydrate diets, 219  
 Lp(a), 31-32  
 in CAD patients, 61  
 CHD risk and, 63, 72, 86, 110t  
 excess, 55t, 71-72  
 as marker for CHD propensity, 63  
 steroids and, 84, 86  
 in women, pre- and postmenopausal, 331-332, 337  
 LPL. See *Lipoprotein lipase*.  
 Lp-X (lipoprotein-X), 91  
 LRC-CPPT (Lipid Research Clinics Coronary Primary Prevention Trial), 174-175, 177t, 281, 281t, 282-283  
 LRP (LDL receptor-like protein), 26  
 LUNAR (Limiting Undertreatment of Lipids in ACS with Rosuvastatin) trial, 138  
 Lupus erythematosus, systemic, 80t  
 LXRs. See *Liver X receptors*.  
 Lymphoma, 80t  
 Lyon Diet Heart Study, 226-227, 228t
- MAAS (Multicentre Anti-Atheroma Study), 144, 149-151, 152t  
 Make Early Diagnosis and Prevent Early Deaths project. See *MED-PED-FH*.  
 Management of lipids. See *Treatment of lipid disorders*.  
 MARS (Monitored Atherosclerosis Regression Study), 144, 146-147, 148t, 149, 183, 195t  
 MED-PED-FH (Medical Pedigrees With FH to Make Early Diagnosis and Prevent Early Deaths), 64  
 Mediterranean Diet Study, 206  
 Mediterranean style diets, 226-227  
 MEGA (Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese) trial, 179  
 Menopause, 332-333, 336-338  
 Metabolic syndrome. See also *Exercise, lipids, and metabolic syndrome*:  
*Insulin resistance*.  
 ATP III and, 15, 378  
 CHD risk and, 15-16, 93  
 clinical appraisal/identification of, 110-112, 111t  
 clinical criteria for, 15, 111t  
 clinical tips, 250, 251  
 familial combined hyperlipidemia and, 38  
 familial hypertriglyceridemia and, 45  
 obesity and, 15, 346  
 risk factors for, 17t
- Metabolic syndrome (*continued*)  
 screening for, 378  
 statin-fibrate combination for, 307-308, 380  
 treatment of, 112, 113, 380-381  
 Metabolism of lipoproteins, 23-30  
 METEOR (Measuring Effects on Intima-Media Thickness), 195t  
 Metoprolol, 83  
 Mevacor, 256. See also *Lovastatin*.  
 cost, 278t  
 preparations and dosing regimens, 259t  
 MI. See *Myocardial infarction*.  
 Micronized fenofibrates, 186t, 189, 297. See also *Fenofibrates*.  
 Microsomal triglyceride transfer proteins (MTPs), 25  
 MIRACL (Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering) trial, 132-133, 133t, 135t  
 Monitored Atherosclerosis Regression Study. See *MARS*.  
 Monotherapy trials, 143-146. See also *Clinical trials and research studies*.  
 Monounsaturated fats (MUFAs), 212t, 218-219  
 MRC/BHF Heart Protection Study, 206  
 MRFIT (Multiple Risk Factor Intervention Trial), 14, 14t  
 meta-analysis, 128t  
 MTPs (microsomal triglyceride transfer proteins), 25  
 MUFAs (monounsaturated fats), 212t, 218-219  
 Multicentre Anti-Atheroma Study. See *MAAS*.  
 Multidrug transporter protein (MTP2), 285  
 Multinational (Pravastatin Multinational Study Group for Cardiac Risk Patients) trial, 150t  
 Multiple Risk Factor Intervention Trial. See *MRFIT*.  
 Myocardial infarction (MI), 62, 123, 336-337  
 β-blockers and, 81, 83  
 fibrates and, 118  
 lipid changes after, 138, 138t  
 non-ST-segment elevation (NSTEMI), 127, 138  
 ST-segment elevation (STEMI), 127, 138  
 Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering trial.  
 See *MIRACL*.  
 Myopathy, 269-272, 269t, 274
- n-3 Fatty acids and fish oils, 301-303  
 adverse effects, 303  
 clinical tip, 303  
 cost, 279t, 303  
 indications for, 256t  
 mechanism of action and metabolism, 256t, 302-303  
 preparations and dosing regimens, 259t  
 National Cholesterol Education Program. See *NCEP*.  
 National Health and Nutrition Evaluation Survey. See *NHANES*.  
 National Heart, Lung, and Blood Institute (NHLBI), Family Heart Study, 38  
 National Institutes of Health (NIH), 35  
 NCEP (National Cholesterol Education Program), 13-14. See also *ATP III (Adult Treatment Panel III)*.  
 diet recommendations, 211-212, 212t  
 goals of, 14  
 screening recommendations, 99-101  
 Nephrotic syndrome, 58, 80t, 92, 342  
 NHANES (National Health and Nutrition Evaluation Survey), 15, 343, 344-345, 344t

- NHANES II (National Health and Nutrition Evaluation Survey II), 348, 348, 357-358, 358
- NHLBI Family Heart Study  
atherosclerosis and familial combined hyperlipidemia, 38, 183  
CHD and familial hypertriglyceridemia, 69  
metabolic syndrome and familial hypertriglyceridemia, 45
- NHLBI Type II Coronary Intervention Study, 283
- Niacin. *See Nicotinic acid.*
- Niacinamide (nicotinamide), 289
- Niacor, 258t, 278t
- Niaspan, 258t, 278t, 291
- Nicotinamide (niacinamide), 289
- Nicotine delivery, forms of smoking compared, 88
- Nicotinic acid (niacin), 287-293. *See also Niacin.*  
adverse effects, 290-293, 290t  
clinical tips, 289, 306  
clinical trials with, 157, 159-160, 162t-163t, 165-172, 166t, 197, 289  
in combination therapies, 304-306, 304t  
doses and side effects in, 306  
nicotinic acid/bile acid sequestrants, 304t, 306, 307  
nicotinic acid/bile acid sequestrants/statins, 304t, 306  
nicotinic acid/ezetimibe, 305  
nicotinic acid/lovastatin, 259t  
nicotinic acid/simvastatin, 259t, 279t  
nicotinic acid/statins, 304t, 305-306  
cost, 278t, 293  
for diabetic patients, 363  
drug interactions, 274, 274t  
efficacy—clinical and atherosclerosis end points, 289  
efficacy—effects on plasma lipoproteins, 289  
as first-line drug for hypertriglyceridemia and low HDL-c, 287  
for high triglycerides, 117  
hints to improve compliance, 292-293, 292t  
indications for, 256t  
for low HDL-c, 117, 119  
mechanism of action and metabolism, 256t, 287-289  
preparations and dosing regimen, 258t  
side effects, minimizing, 292-293, 292t
- Niemann-Pick C1-Like 1 (NPC1L1), 285, 294
- NIH (National Institutes of Health), 35
- Nitric oxide  
fibrates and, 295  
oxidized LDL and, 31  
statins and, 267
- NMR (nuclear magnetic resonance), 56
- NNT (number needed to treat), 133t, 178-179
- Non-HDL-cholesterol (non-HDL-c), 57  
calculation of, 100  
goals for, 116t  
as predictor of CHD risk, 101  
screening for, 100, 101  
as secondary treatment target, 126
- Non-LDL-lowering trials, 183-188, 186t-187t
- Nonmetabolic diseases, 80t, 91-92
- Norgestimate, 85
- NORVIT trial, 234t-235t
- Norway Vitamin trial. *See NORVIT trial.*
- NPC1L1 (Niemann-Pick C1-Like 1), 285, 294
- Nuclear magnetic resonance (NMR), 56
- Number needed to treat (NNT), 133t, 178-179
- Nurses' Health Study, 242, 345t, 347, 356
- OATP1B1, 262, 270, 271, 307
- Obesity  
body fat distribution, 347, 350-351, 351  
body mass index (BMI), 344-345, 345t, 347-351, 348, 350  
CHD risk and, 15-16, 344-346, 345t  
clinical trials and, 222, 343-349  
HDL and HDL-c levels and, 347t, 348-349, 348  
LDL and LDL-c levels and, 347t, 348-349, 348, 350  
lipoprotein disorders and, 343-344, 347-351, 347t  
metabolic syndrome and, 15  
prevalence of, 343-344, 344t  
secondary hyperlipoproteinemia and, 80t, 90  
visceral, 350-351, 351  
VLDL and, 347, 347t
- Olanzapine, 88
- Omega 3 fatty acids, 180, 229t, 279t
- Oral contraceptives, 86, 333
- Ornish diet, 222-224, 223
- Osler, William, 53
- Osteoporosis, possible statin benefits for, 268
- Oxidized LDL, 30-31, 31t, 33
- Pancreatitis  
chylomicronemia and, 73-74  
lipoproteins and, 34-35  
medications and, 81  
severe hypertriglyceridemia and, 19, 71, 114
- Paraproteinemias, 71
- Paraproteins, 89
- Partial ileal bypass trials, 156-157, 158t
- Pathobiological Determinants of Atherosclerosis in Youth study.  
*See PDAY study.*
- Pathophysiology of hyperlipoproteinemias. *See Hyperlipoproteinemias.*
- PCSK9, 27  
gain of function (autosomal dominant) mutations, 36t, 39
- PDAY (Pathobiological Determinants of Atherosclerosis in Youth) study, 124-126, 126, 345-346
- Pediatric patients. *See also Children.*
- Peoples Gas Company study, 128t
- PEPI (Postmenopausal Estrogen/Progestin Intervention) trial, 84, 85t, 337
- Peripheral vascular disease, 378
- Peroxisome proliferation-activated receptor. *See PPAR.*
- Phase Z (A-Z Trial), 133t, 137-138, 168t
- Phenobarbital, 88
- Phenytoin, 88
- Physical activity. *See Exercise, lipids, and metabolic syndrome.*
- Pipe smoking, 88
- PLs. *See Protease inhibitors.*
- PLAC-I (Pravastatin Limitation of Atherosclerosis in the Coronary Arteries I), 144, 150t
- PLAC-II (Pravastatin Limitation of Atherosclerosis in the Coronary Arteries II), 149, 150t, 195t

Plasma lipoproteins. See *Lipoproteins*.

Plasminogen-activator-inhibitor-1 (PAI-1), 110t, 112, 295

Platelet inhibitors, 136

Polygenic LDL elevation, primary, 36t, 39-40, 55t, 66

Polyunsaturated fats (PUFAs), 212t, 217-218, 225-227

POSCH (Program on the Surgical Control Hyperlipidemia) trial, 156-157, 158t

Post-CABG (Post-Coronary Artery Bypass Graft) trial, 171t, 172-173

Postmenopausal Estrogen/Progestin Intervention (PEPI) trial, 84, 85t

Postprandial lipid changes, 243, 244t

PPAR, 293-294, 300, 302

- agonists, 71

Pravachol, 256, 259t, 279t. See also *Pravastatin*.

Pravacor. See *Lovastatin*.

Pravastatin, 88, 256

- in children/adolescents, 329
- clinical trials, 133t, 135t, 136-137, 149, 150t
  - long-term intervention, 161, 167t, 194t
  - PLAC-I and II, 149, 150t, 195t
  - primary prevention, 176t-177t, 177t, 178, 179, 181
  - secondary prevention, 166t-167t
  - vs atorvastatin, 151-155, 154t, 166t, 173, 266
- cost, 279t
- for diabetic patients, 364
- drug interactions, 274, 275t, 284
- efficacy, 264t
- mechanism of action, 256
- metabolic parameters, 261t, 262
- preparations and dosing regimens, 259t

Pravastatin in Elderly Individuals at Risk of Vascular Disease.

- See *PROSPER trial*.

Pravastatin Limitation of Atherosclerosis in the Coronary Arteries I, II.

- See *PLAC-I, PLAC-II*.

Pravastatin or Atorvastatin Evaluation and Infection Therapy trial.

- See *PROVE-IT trial*.

Prednisone, 84, 93

Pregnancy and lactation, 80t, 90-91

- hemoglobin A1C target for, 351
- pancreatitis risk and, 114
- statins during, 273

Premarin, 85t

Premature CHD. See *CHD (coronary heart disease), premature*.

Prevalite, 276. See also *Cholestyramine*.

- cost, 278t
- preparations and dosing regimen, 258t

Prevention Conference V (AHA), 100

Primary polygenic LDL elevation, 36t, 39-40, 55t, 66

Primary prevention trials, 174-180, 176t-177t. See also *Clinical trials and research studies*.

Progestational agents, 84, 85-86, 85t

Progestins, 80t

Program on the Surgical Control Hyperlipidemia trial. See *POSCH trial*.

Proprotein convertase subtilisin kexin 9. See *PCSK9*.

PROSPER (Pravastatin in Elderly Individuals at Risk of Vascular Disease) trial, 167t, 174, 193, 340-342

Protease inhibitors (PIs), 80t, 87-88

Protease PCSK9, gain of function mutations, 36t, 39

PROVE-IT (Pravastatin or Atorvastatin Evaluation and Infection Therapy) trial, 133t, 135t, 136-137, 167t, 173

PROVE-IT-TIMI trial, 266

Provera, 85t

Psyllium, 220, 283

PUFAs (polyunsaturated fats), 212t, 217-218, 225-227

QCA (quantitative coronary angiography), 156

Quantitative coronary angiography (QCA), 156

Questran and Questran Light, 258t, 276, 278t. See also *Cholestyramine*.

RADIANCE-1 (Rating Atherosclerotic Disease Change by Imaging with a New CETP Inhibitor), 197, 198t

Raloxifene, 86, 332

Rancho Bernardo Study, 242

Ranitidine, 88

Rating Atherosclerotic Disease Change by Imaging with a New CETP Inhibitor.

- See *RADIANCE-1*.

Readings and reference sources. See *Reading lists at end of each chapter*.

REGRESS (Regression Growth Evaluation Study), 144, 150t, 195t

Renal disease, 91-92

Renal failure, 80t, 296

Research trials and studies. See *Clinical trials and research studies*.

Resins. See *Bile acid sequestrants*.

Retinoids/retinoic acid, 80t, 86-87

REVERSAL (Reversal of Atherosclerosis with Aggressive Lipid Lowering) trial, 151-155, 154t

Rhabdomyolysis, 269, 271-272, 307

Risk. See also *CHD (coronary heart disease)*.

- attributable, 340-341
- categories, 20t, 102-107, 108t-109t, 379t
- CHD risk equivalents, 101, 378
- emerging risk factors, 107, 110t, 112, 129
- multiple risk factors, 16t, 110-112, 110t, 378
- status and guidelines, 18, 19

Ritonavir, 87

Rosiglitazone, 80t

Rosuvastatin, 196-197, 256

- clinical trials
  - ASTEROID trial, 155-156
  - LUNAR trial, 138
  - METEOR, 195t
- cost, 279t
- drug interactions, 274, 275t, 276
- efficacy, 263, 264t
- mechanism of action, 256
- metabolic parameters, 261t, 262
- preparations and dosing regimens, 259t

SAFARI trial, 308

SANDS trial, 196-197

Saturated fats, 212t, 215-217, 216t

Scavenger receptors, 27, 28, 29

- atherosclerosis and, 30
- B1 (SR-B1), 28, 29
- type A, 30

SCOR FH Intervention Trial, 73t

## Screening

- for children/adolescents, 328-329
- family, 58, 64
- lipid, 99-101

SCRIP (Stanford Risk Intervention Project), 160, 164t

Secondary hyperlipoproteinemias, 79-97, 80t. See also *Hyperlipoproteinemias*.

4 D's mnemonic (diet, drugs, disorders of metabolism, diseases), 79

causes of, summary, 80t

diet and, 79-81, 80t

diseases (nonmetabolic) and, 80t, 91-92

- liver disease, 91
- nephrotic syndrome, 92
- renal disease, 91-92

disorders of metabolism and, 80t, 89-91

- diabetes mellitus, 90
- hypothyroidism, 89
- obesity, 90

pregnancy and lactation, 90-91

drugs and, 80t, 81-89

cardiovascular drugs, 82-84, 82

diuretics, 82-83, 82

endocrine drugs, 84-86, 85t

other frequently used drugs, 86-89

in elderly patients, 342

transplantation and, 92-93

Secondary prevention trials, 160-174, 166t-170t. See also *Clinical trials and research studies*.

Selective uptake, LDL clearance by, 28

Severe hypertriglyceridemia. See *Under Hypertriglyceridemia*.

Severe primary polygenic LDL elevation, 36t, 39-40

Simcor, 259t, 279t, 308

Simvastatin, 256

adverse effects, 273

in children/adolescents, 329

clinical trials, 132, 133t, 135t, 137-138, 144, 149-151, 152t, 163t, 191t

with apheresis, 182-183, 184t, 194t

ezetimibe with, 197, 199, 200t

secondary prevention trials, 160-165, 166t, 168t-169t, 173-174

in combination therapy

simvastatin/ezetimibe, 305

simvastatin/nicotinic acid, 305-306

cost, 279t

cost of, 276, 278t

dose-response curve, 276

drug interactions, 274, 275t, 276

efficacy, 263, 264t

mechanism of action, 256

metabolic parameters, 261t, 262

preparations and dosing regimens, 259t

vs atorvastatin, 263

Sirolimus, 93

Slo-Niacin, 163t

Small, dense LDL, 32-33, 32t, 214, 357, 358

Smoking. See *Cigarette smoking*.

Special populations, 325-376. See also *specific topics*.

children and adolescents, 325-331

diabetic patients, 356-364

Special populations (*continued*)

elderly, 340-343

insulin-resistance, 351-355

obesity, 343-351

women, 331-340

SR-B1 (scavenger receptor B1), 28, 29

SREBPs (sterol regulatory binding proteins), 26, 280, 302

St Thomas' Arteriosclerosis Regression Study. See *STARS*.

Stanzolol, 84

Stanford Risk Intervention Project. See *SCRIP*.

STARS (St. Thomas Arteriosclerosis Treatment Study), 146, 215, 283

Statin trials meta-analysis. See *CTT*.

Statins and statin therapies, 88, 255-276. See also *specific drugs*.

adverse effects, 268-273, 269t

in children/adolescents, 328

clinical trials. See *Clinical trials and research studies*.

in combination therapy, 304-308, 304t

doses and side effects in, 306

statins/bile acid sequestrants, 304t, 305

statins/bile acid sequestrants/nicotinic acid, 304t, 306

statins/ezetimibe, 304t, 305, 306

statins/fibrates, 304t, 307-308, 364, 380

statins/nicotinic acid, 304t, 305-306

cost, 276, 278t-279t

for diabetic patients, 361-363

dosing, 18, 259t

dose-response curve, 276, 280

drug interactions, 271-272, 274-276, 275t, 300

efficacy—clinical and atherosclerosis end points, 266-268

efficacy—lipid effects, 262-265, 264t

as first-line drugs, 18, 362

grapefruit juice and, 274

HDL-c level and, 119

mechanism of action and drug metabolism, 256-262, 256t, 257t

preparations and dosing regimens, 259t

selection of, 263-265

in transplantation patients, 87, 93

treatment of coronary syndromes, 135t

Steroids

anabolic, 71, 80t, 84

lipid levels and, 80t, 81, 84-86, 85t, 93

pancreatitis risk and, 81

use in transplantation, 93

Sterol regulatory binding proteins. See *SREBPs*.

Sterols, plant, 40. See also *Beta sitosterolemia*.

Stockholm Ischemic Heart Disease Study, 289

STOP-Hypertension (Swedish Trial in Old Patients with Hypertension), 340

STRIDE (Studies of a Targeted Risk Reduction Intervention Through Defined Exercise) trial, 248-250, 249t

Studies and trials. See *Clinical trials and research studies*.

Studies of a Targeted Risk Reduction Intervention Through Defined Exercise trial. See *STRIDE trial*.

Study on Prevention of Coronary Atherosclerosis by Intervention with Marine Omega-3 Fatty Acids, 229t

Supplements. See *Vitamins and supplements*.

Surgeon General's Report on Physical activity, 245-247

Swedish Trial in Old Patients with Hypertension. See *STOP-Hypertension*.

Systemic lupus erythematosus, 80t

Tamoxifen, 86  
 Tangier disease, 45  
 Ten-year risk assessments, 102, 104t-107t, 378  
 Tendinopathy, 272  
 Tendon xanthomas, 62, 63  
 Teratogenicity, statins and, 272-273  
 Terbutaline, 88  
 Testosterone, 84  
 TFAs (trans fatty acids), 146, 217  
 TGs. See *Triglycerides (TGs)*.  
 Therapeutic Lifestyle Change. See *Diet and TLC (Therapeutic Lifestyle Change)*.  
 Therapy goals. See *Clinical appraisal and therapy goals*.  
 Thiazolidinediones, 89  
 Thromboembolism, 332, 336-337  
 Thyroid abnormalities, 84. See also *Hypothyroidism*.  
 Timolol eye drops, 88  
 TLC (Therapeutic Lifestyle Change). See *Diet and TLC*.  
 TNT (Treat to New Targets) trial, 168t-169t, 173-174  
 Tobacco smoking. See *Cigarette smoking*.  
 TOMHS (Treatment of Mild Hypertension Study), 83  
 Torcetrapib, 34, 119  
   clinical trials, 197-199, 198t  
 Trans fatty acids (TFAs), 146, 217  
 Transdermal estrogen, 86  
 Transplantation, 92-93  
   drugs used in, 87, 93  
   statin benefits for, 267-268  
 Treat to goals component (ACT/treatment algorithm), 380-381  
 Treat to New Targets trial. See *TNT trial*.  
 Treatment algorithm, 377-381  
   ATP III guidelines/ACT (assemble-calculate-treat to goals), 377-381  
     assemble component, 377-378  
     calculate component, 378-380, 379t  
     treat to goals component, 380-381  
   CHD risk-factor status and goals, 377-378, 379t  
   clinical tip, 377  
   data sheet for, 381, 382  
   LDL-c goals, 378-380, 379t  
 Treatment of lipid disorders. See also *specific drugs, drug classes, and topics*.  
   diet and TLC (Therapeutic Lifestyle Change), 211-240  
   drugs and drug therapies, 255-323  
   exercise and metabolic syndrome, 241-254  
   special populations, 325-376  
   treating patients with hyperlipidemia, 18-19  
   treatment algorithm, 377-381  
 Treatment of Mild Hypertension Study (TOMHS), 83  
 Trials and studies. See *Clinical trials and research studies*.  
 TriCor. See also *Fenofibrates*.  
   cost, 278t, 301  
   preparations and dosing, 258t, 294t  
 Triglide. See also *Fenofibrates*.  
   cost, 278t, 301  
   preparations and dosing, 258t, 294t  
 Triglycerides (TGs). See also *Hypertriglyceridemias*.  
   classification of, 115t  
   clinical appraisal of, 113-117, 115t, 116t  
   exercise and, 242-243, 244t

Triglycerides (TGs) (*continued*)  
 high  
   acute pancreatitis risk with, 114  
   disorders associated with, 55t  
   disorders of, 66-67  
   treatment of, 114-116, 117  
   measurement of, 114, 116  
   statins and, 263  
   steroids/estrogens and, 81  
   synthesis of, 26  
   in treatment algorithm, 377  
 Type A scavenger receptors, 30  
 Type III hyperlipoproteinemia (familial dysbetalipoproteinemia), 41-42, 41t, 55t, 69

UCSF-SCOR (University of California, San Francisco, Specialized Center for Atherosclerosis Research) trials, 159, 163t  
 UKPDS trial, 182

VA-HIT (Veterans Affairs HDL-c Intervention Trial), 118, 185-189, 187t, 191t-192t, 296, 297, 298-299, 362  
 VAP (vertical auto-profile) procedure, 56  
 Vegetarian diets, 233-236  
 Vertical auto-profile (VAP) procedure, 56  
 Very-low-density lipoproteins. See *VLDLs*.  
 Veterans Affairs HDL-c Intervention Trial. See *VA-HIT*.  
 Visceral obesity, 112, 251, 350-351. See also *Obesity*.  
 Vitamins and supplements. See also *Diet and TLC (Therapeutic Lifestyle Change)*.  
   antioxidants, 230-231, 339  
   B<sub>6</sub> and B<sub>12</sub>, 232-233, 234t-235t, 339  
   clinical trials, 157, 159-160, 162t-163t  
   D, 342  
   E, 230-231  
   folic acid, 232-233, 234t-235t, 339  
   niacin. See *Nicotinic acid (niacin)*.  
 VLDL (very-low-density lipoprotein), 26-27  
   bile acid sequestrants and, 281-282  
   composition and size, 24t, 26  
   fibric acid derivatives and, 295  
   function of, 23-25, 26  
   genesis and fate of, 26-27  
   levels  
     in familial combined hyperlipidemia, 36-38, 36t  
     in familial dysbetalipoproteinemia, 69  
     in familial hypertriglyceridemia, 44-45  
     in hypertriglyceridemias, 43t  
     insulin resistance and, 353-354, 354t, 355  
     maximizing reduction in, 306  
     obesity and, 347, 347t  
   nicotinic acid and, 288  
   pancreatitis and, 35  
   remnants of (intermediate-density lipoproteins), 27, 69  
   statins and, 256-260  
 Vytorin, 259t, 305  
   cost, 279t, 308

Warfarin, drug interactions, 276, 284, 300

Weight. See also *Metabolic syndrome; Obesity*.  
excess body weight, 212  
increase, 111-112, 343-344, 344t  
as independent risk factor, 346

Weight Watchers diet, 222-224, 223

WelChol, 276. See also *Bile acid sequestrants; Colesevelam*.  
cost, 278t  
preparations and dosing regimen, 258t

West of Scotland Coronary Prevention Study. See *WOSCOPS*.

WHI (Women's Health Initiative) trial, 85, 223-224

WHO (World Health Organization) Clofibrate Trial, 296

Women, 331-340  
ALPHA prevention strategies, 338-340, 339t  
antiatherosclerosis treatment in, 333-340  
clinical tips, 332-333, 338  
CVD/CHD risk and, 331-338, 334t  
estrogens/progestins, 332-333, 337, 339  
lipid levels and, 332-333  
oral contraceptives, 333  
transdermal estrogen patches, 332-333  
Framingham risk factors, 335t  
menopause, 332-333, 336-338

Women's Health Initiative (WHI) trial, 85, 223-224

WOSCOPS (West of Scotland Coronary Prevention Study), 175, 177t, 178, 364

Xanthomas  
in autosomal recessive hypercholesterolemia, 40  
in beta sitosterolemia, 40-41  
in chylomicronemia, 74-75, 74  
in familial dysbetalipoproteinemia (familial Type III), 69, 70  
in familial hypercholesterolemia, 62, 63-64, 63  
olanzapine and, 88

Zetia. See also *Ezetimibe*.  
preparations and dosing regimen, 258t

Zocor, 256. See also *Simvastatin*.  
cost, 276, 278t  
preparations and dosing regimens, 259t

Zone diet, 222-224, 223